In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
395 News Items found
Group photo of researchers Michael Berger, Marc Ladanyi, Dana Tsui, Rose Brannon, Ryma Benayed, Ahmet Zehir, and David Klimstra.
Feature
How MSK-ACCESS Blood Test for Cancer was Created

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Nat, Alex, and Michael Wolff and Polly Draper
Fixing One Wrong Note: How MSK Precision Diagnostics Saved a Musician With a Rare Cancer

Learn how molecular testing and an experimental targeted therapy cured jazz musician Michael Wolff, who had the rare cancer histiocytic sarcoma.
MSK medical oncologist Alexander Drilon
Feature
First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
Memorial Sloan Kettering Collaborates with Global Community on the Bloomberg New Economy International Cancer Coalition to Accelerate and Expand Access to New Therapies and Clinical Trials

The Coalition was discussed at the fourth annual Bloomberg New Economy Forum (NEF) in Singapore on November 16–19.
SKI scientists David Scheinberg and Derek Tan
Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs

These souped-up versions may help overcome some limitations of existing CAR T cells.
Microscopy image showing a quiescent cluster of lung adenocarcinoma tumor cells with low STING expression.
MSK Scientists Identify Potential New Strategy Against Metastasis

A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
Memorial Sloan Kettering surgeon Prasad Adusumilli
Q&A
CAR T Cell Therapy Shows Promise for Treating Mesothelioma

A combination immunotherapy approach using CAR T cells could be an effective new way to treat mesothelioma.
A Fred’s Team runner giving a high five
Your Impact: Celebrating Our Donors’ Support in 2021

Learn about how our donor community is funding life-changing cancer research at Memorial Sloan Kettering and ensuring a brighter future for people with cancer around the world.
a lab coat hangs in an MSK lab
MSK Research Highlights, March 20, 2026

New MSK research discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.
Female doctor in white coat examining patient with stethoscope.
Feature
Shorter, Safer, Smarter: How MSK Enhances Radiation Therapy for Breast Cancer

MSK leads the way in optimizing radiation treatment for breast cancer patients.